Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.53 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 2/20 | 0.48 |
| ▸ | CPB1 | P15086 | 1/20 | 0.48 |
| ▸ | CPA3 | P15088 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29903902 | 1.00 | L3MBTL1 (0.61) | L3MBTL1ALDH1A1GAAPOLBTDP1 | |
| SCHEMBL146867 | 1.00 | L3MBTL1 (0.61) | L3MBTL1ALDH1A1GAAPOLBTDP1 | |
| SCHEMBL377609 | 1.00 | L3MBTL1 (0.61) | L3MBTL1ALDH1A1GAAPOLBTDP1 | |
| SCHEMBL23782080 | 0.98 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1GAAPOLBTDP1 | |
| SCHEMBL6739142 | 0.98 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1GAAPOLBTDP1 | |
| SCHEMBL11137284 | 0.91 | L3MBTL1 (0.71) | L3MBTL1ALDH1A1GAAPOLBTDP1 | |
| SCHEMBL3274728 | 0.89 | ALDH1A1 (0.51) | L3MBTL1ALDH1A1GAAPOLBTDP1 | |
| SCHEMBL28306756 | 0.88 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1GAAPOLBTDP1 | |
| SCHEMBL10717750 | 0.87 | MEN1 (0.54) | L3MBTL1ALDH1A1GAAPOLBTDP1 | |
| SCHEMBL9736992 | 0.86 | GABBR2 (0.53) | L3MBTL1ALDH1A1GAAPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117105931-A | Method for preparing pyridopyrimidine compounds and intermediate thereof | 上海翰森生物医药科技有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-108884081-B | Process for separating enantiomers of piperazine derivatives | 阿森纽荣股份公司 | 2022-11-01 | — | — | CN | claimed |
| EP-3419974-B1 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2021-05-05 | — | — | EP | claimed |
| US-10344021-B2 | Process for the separation of enantiomers of piperazine derivatives | ASCENEURON S A (CH) | 2019-07-09 | — | — | US | claimed |
| EP-3419974-A1 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | Asceneuron SA (CH) | 2019-01-02 | — | — | EP | claimed |
| CN-108884081-A | The method for separating the enantiomer of bridged piperazine derivatives | 阿森纽荣股份公司 | 2018-11-23 | — | — | CN | claimed |
| WO-2017144635-A1 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | claimed |
| US-20070270487-A1 | Novel process and intermediates 085 | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | claimed |
| US-20250368642-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250368643-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12398130-B2 | Acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2025-08-26 | — | — | US | disclosed |
| US-12391691-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12391689-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250206735-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-06-26 | — | — | US | disclosed |
| WO-2006032023-A2 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058393-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-16 | — | — | US | disclosed |
| US-20050124698-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | CYMABAY THERAPEUTICS, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005042478-A2 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-12 | — | — | WO | disclosed |
| WO-1995007260-A1 | TETRAHYDROISOQUINOLINES AS ALPHA-2 ANTAGONISTS AND BIOGENIC AMINE UPTAKE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-03-16 | — | — | WO | disclosed |
| US-5389638-A | Nervous system disorders | ABBOTT LABORATORIES (US) | 1995-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344021-B2 | Process for the separation of enantiomers of piperazine derivatives | CYP3A5, CYP4Z1, HTR5A | L3MBTL1 4798/4885ALDH1A1 115/4885GAA 1712/4885 |
| US-20060058393-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | L3MBTL1 3198/4885ALDH1A1 1360/4885GAA 833/4885 |
| US-20070270487-A1 | Novel process and intermediates 085 | CYP3A5, AGPAT5, CYP4F8 | L3MBTL1 4414/4885ALDH1A1 377/4885GAA 961/4885 |
| US-12391691-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | KRAS, NRAS, HRAS | L3MBTL1 3019/4885ALDH1A1 3493/4885GAA 2623/4885 |
| US-20050124698-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | L3MBTL1 3157/4885ALDH1A1 1558/4885GAA 803/4885 |
| US-20250368643-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | L3MBTL1 3019/4885ALDH1A1 3493/4885GAA 2623/4885 |
| US-20250368642-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | L3MBTL1 3019/4885ALDH1A1 3493/4885GAA 2623/4885 |
| US-20250206735-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | L3MBTL1 3019/4885ALDH1A1 3493/4885GAA 2623/4885 |
| US-12398130-B2 | Acid addition salts of piperazine derivatives | DNPEP, GAA, SLC30A5 | L3MBTL1 4743/4885ALDH1A1 63/4885GAA 2/4885 |
| US-12391689-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | KRAS, NRAS, HRAS | L3MBTL1 3019/4885ALDH1A1 3493/4885GAA 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.